A phase II study of high dose epirubicin in unresectable non small cell lung cancer.

Epirubicin (EPI), a doxorubicin analogue, is reported to have equal antitumour activity with lower cardiac and systemic toxicity. Recently, the maximum tolerated dose of this drug has been revised upwards with reported increased response rates in several malignancies. We initiated a phase II study o...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Smit, E. F., Berendsen, H. H., Piers, D. A., Smeets, J., Riva, A., Postmus, P. E.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 1992
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC1977612/
https://ncbi.nlm.nih.gov/pubmed/1313691
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak